Achalasia - ClinicalTrials.gov

Safety and Efficacy of Antireflux Ablation Therapy (ARAT) at Esophagogastric Junction in Patients With Reflux Disease After Peroral Endoscopic Myotomy (POEM) in Achalasia

In the context of esophageal sphincter dysfunction, Achalasia is the inability of the lower esophageal sphincter to relax. The treatment of achalasia has a 90 percent success, according to Heller's myotomy. Compared to alternative therapies such as Heller's myotomy or pneumatic dilatation, the use of achalasia by peroral endoscopic myotomy is associated with a higher risk of gastroesophageal reflux disease. At the level of the esophagogastric junction, a portion of the esophagus's argon plasma may cause reconstruction of this region, resulting in partial stenosis and thus reduced the passage of gastric or gastroduodenal material into the esophagus. A clinical trial will be carried out, including those with achalasia of peroral myotomy older than 18 years old, with abnormal acid exposure in the pH measurement 3 months or more after therapy, who accept the management of ablation with hybrid argon plasma.

Source link: https://clinicaltrials.gov/ct2/show/NCT04065516

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions